Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S. and Canada by the drug company Eli Lilly and Co. The initial dose is 400 mg/m2 administered over 120 minutes and Cetuximab is available in 100 mL vials containing 200 mg of drug.
(a) Calculate the initial dose for a patient weighing 140-lb and 65 inches in height.
(b) Calculate the volume of product needed to meet the dose.
(c) The package insert warns that the infusion rate should not
exceed 10 mg/minute. If the infusion is given over 120 minutes, is
this compliant with the warning?
A. The intial dose for the patient is 660.4 mg.
B. 330.2 ml of volume of product is needed to meet the dose.
C. For this particular patient the required initial dose is 660.4 mg. If the drug is given over 10mg \ min then 66.04 min is required to complete the dose. It may used as warning in over height patients but it is not a warning in this particular patient.
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal...
The biotechnology drug cetuximab (ER-BITUX), used in the treatment of colorectal cancer, has a loading dose of 400 mg/m2administered as an intravenous infusion over a 120-minute period. Using an IV set that delivers 15 drops/mL, calculate (a) the dose (in mg) for a patient with a BSA of 1.6 m2, and (b) the rate of delivery, in drops/min, for 250 mL of an IV fluid containing the dose.
Pertuzumab is a recombinant monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) protein. Pertuzumab can be used in the treatment of specific metastatic breast cancers in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. The HER signaling pathway plays a role in the formation and growth of numerous cancers, and pertuzumab binds to the HER2 receptor to inhibit the ability of HER2 to interact with other HER family members on the...